anti-hbv

Chamaechromone is a natural product isolated from the roots of Stellera chamaejasme L.. Chamaechromone has anti-HBV and insecticidal activity.

Tenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.

Punicalagin is a major ellagitannin found in pomegranates that is reported to produce antioxidant, anti-inflammatory, and anticancer effects. It has been shown to prevent high-fat diet-induced obesity-associated accumulation of cardiac triglyceride and ch

Punicalin exerts anti-inflammatory, antioxidative, and anti-hepatotoxic activities, it shows inhibitory activity on HIV-1 reverse transcriptase in a dose-dependent manner, with an IC50 of 0.11 microg/ml (0.14 microM).

Helioxanthin derivative 5-4-2 (Helioxanthin 5-4-2) is an analogue of helioxanthin that shows anti-HBV activity in vitro and can be used to study HBV.

Isothiafludine (NZ-4) is an orally active anti-HBV compound that acts by blocking the encapsulation of pre-genomic RNA (pgRNA) and interfering with nucleosome capsid assembly, and is used in the study of HBV infections.

Metacavir (PNA) is a novel nucleoside reverse transcriptase inhibitor, a deoxyguanosine analog, with anti-hepatitis B virus (HBV) activity and mitochondrial toxicity, which can be used to study HBV infection.

DDG-39 (1-(2,3-dideoxy-2-fluoropentofuranosyl)cytosine) possesses antiviral activity with potent and selective anti-HIV-1 and HBV activity in cell culture. The average antiviral IC50 is 0.61 μM.

Catalpol (Catalpinoside) is an iridoid glycoside with neuroprotective, anti-inflammatory, and anti-hepatitis virus effects.

Cetylpyridinium Chloride (Hexadecylpyridinium Chloride) is a cationic quaternary ammonium compound used as oropharyngeal antiseptic.

Tenofovir diphosphate TEA (TFV-DP TEA) is the triethylamine salt of TFV-DP, an ATP-competitive DNA polymerase inhibitor that inhibits HIV-1 reverse transcriptase. It has anti-HIV/HBV potential through its incorporation into the viral DNA strand to terminate viral DNA synthesis and thus inhibit viral genome replication.

Helioxanthin 8-1, an analogue of helioxanthin, exhibits significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 μM.

IR415 selectively interacts with Hepatitis B virus X protein (HBx, Kd = 2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease. IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity.

NVR 3-778 is a first-in-class, orally bioavailable HBV CAM belonging to the SBA class, exhibiting anti-HBV activity.

HBV-IN-51 (Compound 17e) is an effective hepatitis B virus (HBV) capsid assembly modulator. It demonstrates significant anti-HBV activity with an EC50 value of 0.033 μM in HepAD38 cells. HBV-IN-51 exhibits good metabolic stability in plasma and is rapidly metabolized in human liver microsomes.

HBV-IN-52 is a selective inhibitor of HBV and a derivative of Neplanocin A, displaying significant anti-hepatitis B virus replication activity with an EC50 of 0.96 μM. It also suppresses the secretion of hepatitis B surface antigen (HBsAg) with an EC50 of 0.82 μM. HBV-IN-52 is useful for studying chronic hepatitis B (CHB) infection.

HBV-IN-45 is a selective and orally bioavailable HBV capsid assembly modulator, with an IC50 of 0.51 μM for HBcAg in HBC cells. [HBV-IN-45] demonstrates potent anti-HBV activity.

Bentysrepinine, a novel anti-HBV agent, inhibits DNA-HBV and cccDNA activities for the treatment of hepatitis B virus (HBV)-infected hepatitis.

Z060228 is an potent anti-HBV inhibitor. The HBV DNA replication was effectively inhibited by Z060228 in the supernatants of the HepG2.2.15 cells. Z060228 exhibited effects on the self-assembly of Cp149. SEC data revealed that Z060228 altered the equilibr

1. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) has antiviral activity, including anti-HIV-1 integrase activity. 2. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) shows anti-hepatotoxic activity.

HBV-IN-4, a derivative of phthalazinone, functions as a potent, orally active inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. It effectively induces the formation of genome-free capsids, demonstrating significant anti-HBV potency[1].

6-Chloro-2-fluoropurine is a heterocyclic building block.1,2It has been used in the synthesis of purine nucleosides that inhibit cyclin-dependent kinases (CDKs)in vitro.16-Chloro-2-fluoropurine has also been used in the synthesis of purine nucleosides that are active against HIV-1 and hepatitis B virus (HBV)in vitro.2 1.Wilson, S.C., Atrash, B., Barlow, C., et al.Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitorsBioorg. Med. Chem.19(22)6949-6965(2011) 2.Lee, K., Choi, Y., Gullen, E., et al.Synthesis and anti-HIV and anti-HBV activities of 2'-fluoro-2',3'-unsaturated L-nucleosidesJ. Med. Chem.42(7)1320-1328(1999)

1, 2, 3, 4, 6-Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) and gallic acid from Pistacia lentiscus have antimutagenic and antioxidant activities. 2. 1, 2, 3, 4, 6-Penta-O-galloyl-beta-D-glucose (PGG) possesses potent anti-proliferative and anti-invasive effects, it also has inhibition of inducible nitric oxide synthase and cyclooxygenase-2 activity. 3. PGG may serve as a model for the development of new types of anti-diabetic and anti-metabolic syndrome therapeutics. 4. 1, 2, 3, 4, 6-Penta- O -galloyl-β- d -glucose has vasodilatory and anti-inflammatory effects, it dilates vascular smooth muscle and suppresses the vascular inflammatory process via endothelium-dependent nitric oxide (NO)/cGMP signaling. 5. 1, 2, 3, 4, 6-Penta-O-galloyl-beta-D-glucose can decrease the level of extracellular hepatitis B virus (HBV) (IC5, 1. microg/ml) in a dose-dependent manner, it also can reduce the HBsAg level by 25% at a concentration of 4 microg/ml; the gallate structure of PGG may play a critical role in the inhibition of anti-HBV activity, suggests that PGG could be a candidate for developing an anti-HBV agent. 6. 1, 2, 3, 4, 6-Penta-O-galloyl-β-D-glucose has anti-parasitic activity, displays an EC5 value of 67 μM, at least 6.6-fold more effective than the standard drug benznidazole against trypomastigote forms of T. cruzi.

Firzacorvir, a cyclic sulfamide compound, functions as an HBV core protein modulator and demonstrates potent anti-HBV activity, with an EC50 value of < 1 μΜ.